Midazolam selectively potentiates the A(2A) - but not A1- receptor--mediated effects of adenosine: role of nucleoside transport inhibition and clinical implications

Anesthesiology. 2000 Feb;92(2):567-77. doi: 10.1097/00000542-200002000-00041.

Abstract

Background: Inhibition of adenosine metabolism offers a unique approach to harness the cardioprotective properties of adenosine in a site- and event-specific manner. Benzodiazepines inhibit adenosine metabolism by blocking nucleoside transporter. Therefore, the authors studied the binding affinities of structurally different benzodiazepines to nucleoside transporter and benzodiazepine-induced potentiation of A1-adenosine (negative dromotropy) and A2A-adenosine (coronary vasodilation) receptor-mediated effects.

Methods: In membranes from porcine striatum and guinea pig ventricle, competition binding assays to displace [3H]nitrobenzylmercaptopurine riboside ([3H]NBMPR) from nucleoside transporter were performed using alprazolam, chlorodiazepoxide, diazepam, flurazepam, and midazolam. The augmentation by the most potent benzodiazepine of A1- and A2A-adenosine receptor-mediated responses, elicited by exogenous administration of adenosine or brief periods of global hypoxia, was subsequently studied in guinea pig Langendorff-perfused hearts.

Results: All benzodiazepines completely displaced [3H]NBMPR in a concentration-dependent manner with Hill coefficients not significantly different from unity in both striatal and ventricular membranes. Midazolam was the most potent inhibitor of nucleoside transporter (ventricle:pKi = 5.22+/-0.41, Ki = 6 microM). In isolated hearts, midazolam (5, 10, 20 microM) significantly augmented coronary flow in a concentration-dependent manner in the presence of adenosine (30 nM), an effect reversed by ZM 241385, a selective A2A-receptor antagonist. In contrast, midazolam did not increase the effect of adenosine (30 nM) on atrioventricular conduction. Similarly, midazolam potentiated A2A- but not A1-receptor-mediated effects of endogenous adenosine released during hypoxia.

Conclusions: Structurally distinct benzodiazepines inhibit nucleoside transporter to different degrees. Midazolam selectively augments A2A- but not A1-receptor-mediated effects of adenosine by inhibiting nucleoside transporter.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine / metabolism
  • Adenosine / pharmacology*
  • Anesthetics, Intravenous / pharmacology*
  • Animals
  • Atrioventricular Node / drug effects
  • Coronary Circulation / drug effects
  • Drug Synergism
  • GABA Modulators / pharmacology*
  • Guinea Pigs
  • Heart / drug effects
  • Heart Conduction System / drug effects
  • Heart Ventricles / drug effects
  • In Vitro Techniques
  • Membranes / drug effects
  • Membranes / metabolism
  • Midazolam / pharmacology*
  • Neostriatum / drug effects
  • Neostriatum / metabolism
  • Nucleosides / metabolism
  • Purinergic P1 Receptor Agonists*
  • Receptor, Adenosine A2A
  • Swine

Substances

  • Anesthetics, Intravenous
  • GABA Modulators
  • Nucleosides
  • Purinergic P1 Receptor Agonists
  • Receptor, Adenosine A2A
  • Adenosine
  • Midazolam